{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:03:49Z","timestamp":1784811829102,"version":"3.55.0"},"reference-count":41,"publisher":"Akademiai Kiado Zrt.","issue":"10","content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2024,3,10]]},"abstract":"<jats:p>Az 1-es t\u00edpus\u00fa diabetes mellitus kr\u00f3nikus lefoly\u00e1s\u00fa, progredi\u00e1l\u00f3 term\u00e9szet\u0171\n                    autoimmun betegs\u00e9g. A genetikai, immunol\u00f3giai \u00e9s a kezdeti anyagcsere-elt\u00e9r\u00e9sek\n                    j\u00f3val megel\u0151zik a klinikai t\u00fcnetek jelentkez\u00e9s\u00e9t, ami m\u00e1r r\u00e9g\u00f3ta felvetette\n                    annak lehet\u0151s\u00e9g\u00e9t, hogy a betegs\u00e9g kialakul\u00e1s\u00e1t k\u00e9sleltess\u00fck, megakad\u00e1lyozzuk,\n                    esetleg visszaford\u00edtsuk. Sajnos a prevenci\u00f3t c\u00e9lz\u00f3 klinikai vizsg\u00e1latok sok\u00e1ig\n                    nem hoztak \u00e1t\u00fct\u0151 sikert. A k\u00f6zelm\u00faltban azonban az immunol\u00f3giai kezel\u00e9s el\u00e9rte\n                    azt a st\u00e1diumot, amelyben az intervenci\u00f3 el\u0151nyei meghaladj\u00e1k a kezel\u00e9ssel j\u00e1r\u00f3\n                    kock\u00e1zatot. E lehet\u0151s\u00e9gek napi gyakorlatba \u00fcltet\u00e9se, az inzulinkezel\u00e9s\n                    k\u00e9sleltet\u00e9s\u00e9nek lehet\u0151s\u00e9ge \u00e1t fogja form\u00e1lni a betegs\u00e9g kezel\u00e9s\u00e9nek, illetve az\n                    1-es t\u00edpus\u00fa cukorbetegs\u00e9g tekintet\u00e9ben a nagy kock\u00e1zat\u00fa betegek felkutat\u00e1s\u00e1nak\n                    eddigi strat\u00e9gi\u00e1j\u00e1t. A szerz\u0151k \u00f6sszefoglalj\u00e1k az e k\u00f3rforma immunter\u00e1pi\u00e1j\u00e1val\n                    kapcsolatos legfontosabb ismereteket. Orv Hetil. 2024; 165(10): 363\u2013369.<\/jats:p>","DOI":"10.1556\/650.2024.33000","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T01:03:33Z","timestamp":1710205413000},"page":"363-369","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["Az 1-es t\u00edpus\u00fa diabetes mellitus immunter\u00e1pi\u00e1ja"],"prefix":"10.1556","volume":"165","author":[{"given":"Krisztina","family":"Arapovicsn\u00e9 Kiss","sequence":"first","affiliation":[{"name":"\u00c9szak-budai Szent J\u00e1nos Centrumk\u00f3rh\u00e1z, II. Belgy\u00f3gy\u00e1szat-Diabetol\u00f3gia Budapest, Di\u00f3s \u00e1rok 1\u20133., 1125 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"T\u00f3th","sequence":"additional","affiliation":[{"name":"\u00c9szak-budai Szent J\u00e1nos Centrumk\u00f3rh\u00e1z, II. Belgy\u00f3gy\u00e1szat-Diabetol\u00f3gia Budapest, Di\u00f3s \u00e1rok 1\u20133., 1125 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Schandl","sequence":"additional","affiliation":[{"name":"\u00c9szak-budai Szent J\u00e1nos Centrumk\u00f3rh\u00e1z, II. Belgy\u00f3gy\u00e1szat-Diabetol\u00f3gia Budapest, Di\u00f3s \u00e1rok 1\u20133., 1125 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zs\u00f3fia","family":"Kiss","sequence":"additional","affiliation":[{"name":"Beteg\u00e1pol\u00f3 Irgalmas Rend, Budai Irgalmasrendi K\u00f3rh\u00e1z, Allergol\u00f3gia \u00e9s Immunol\u00f3gia Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Winkler","sequence":"additional","affiliation":[{"name":"\u00c9szak-budai Szent J\u00e1nos Centrumk\u00f3rh\u00e1z, II. Belgy\u00f3gy\u00e1szat-Diabetol\u00f3gia Budapest, Di\u00f3s \u00e1rok 1\u20133., 1125 Magyarorsz\u00e1g"},{"name":"Miskolci Egyetem, Eg\u00e9szs\u00e9gtudom\u00e1nyi Kar, Elm\u00e9leti Eg\u00e9szs\u00e9gtudom\u00e1nyi Int\u00e9zet Miskolc Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos Tibor","family":"Kis","sequence":"additional","affiliation":[{"name":"\u00c9szak-budai Szent J\u00e1nos Centrumk\u00f3rh\u00e1z, II. Belgy\u00f3gy\u00e1szat-Diabetol\u00f3gia Budapest, Di\u00f3s \u00e1rok 1\u20133., 1125 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Noble JA. Immunogenetics of type 1 diabetes: a comprehensive review.\n                    J Autoimmun. 2015; 64: 101\u2013112.","DOI":"10.1016\/j.jaut.2015.07.014"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Redondo MJ, Jeffrey J, Fain PR, et al. Concordance for islet\n                    autoimmunity among monozygotic twins. N Engl J Med. 2008; 359:\n                    2849\u20132850.","DOI":"10.1056\/NEJMc0805398"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Tomasics G, Schandl L, Poly\u00e1k A, et al. Diabetes mellitus and the\n                    intestinal microbiome. [A diabetes mellitus \u00e9s a b\u00e9lmikrobiom.] Orv Hetil. 2023;\n                    164: 981\u2013987. [Hungarian]","DOI":"10.1556\/650.2023.32788"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Kis J, Engelmann P, Farkas K, et al. Reduced CD4+ subset and Th1\n                    bias of the human iNKT cells in type 1 diabetes mellitus. J Leukoc Biol. 2007;\n                    81: 654\u2013662.","DOI":"10.1189\/jlb.1106654"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Lakatos K, Elias KM, Berkowitz RS, et al. The role of natural killer\n                    cells in the immune homeostasis of the maternal fetal interface. [A term\u00e9szetes\n                    \u00f6l\u0151sejtek szerepe az anyai-magzati immunhomeostasis fenntart\u00e1s\u00e1ban.] Orv Hetil.\n                    2022; 163: 734\u2013742. [Hungarian]","DOI":"10.1556\/650.2022.32458"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Orban T, Kis J, Szereday L, et al. Reduced CD4+ T-cell-specific gene\n                    expression in human type 1 diabetes mellitus. J Autoimmun. 2007; 28:\n                    177\u2013187.","DOI":"10.1016\/j.jaut.2007.01.002"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Nagata M, Santamaria P, Kawamura T, et al. Evidence for the role of\n                    CD8+ cytotoxic T cells in the destruction of pancreatic beta-cells in nonobese\n                    diabetic mice. J Immunol. 1994; 152: 2042\u20132050.","DOI":"10.4049\/jimmunol.152.4.2042"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Krischer JP, Lynch KF, Schatz DA, et al. The 6 year incidence of\n                    diabetes-associated autoantibodies in genetically at-risk children: the TEDDY\n                    study. Diabetologia 2015; 58: 980\u2013987.","DOI":"10.1007\/s00125-015-3514-y"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Abbas AK, Murphy KM, Sher A. Functional diversity of helper T\n                    lymphocytes. Nature 1996; 383: 787\u2013793.","DOI":"10.1038\/383787a0"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Martin S, Wolf-Eichbaum D, Duinkerken G, et al. Development of type\n                    1 diabetes despite severe hereditary B-cell deficiency. N Engl J Med. 2001; 345:\n                    1036\u20131040.","DOI":"10.1056\/NEJMoa010465"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Tatovic D, Narendran P, Dayan CM. A perspective on treating type 1\n                    diabetes mellitus before insulin is needed. Nat Rev Endocrinol. 2023; 19:\n                    361\u2013370. Erratum: Auther correction. Nat Rev Endocrinol. 2023; 19:\n                    371.","DOI":"10.1038\/s41574-023-00837-0"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Greenhill C. Interventions in people newly diagnosed with type 1\n                    diabetes mellitus. Nat Rev Endocrinol. 2023; 19: 252.","DOI":"10.1038\/s41574-023-00825-4"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"T\u00f3th A, Schandl L, Kis J, et al. Comparison of the remission phase\n                    in childhood and adult-onset type 1 diabetes. [A remisszi\u00f3s f\u00e1zis\n                    \u00f6sszehasonl\u00edt\u00e1sa gyermek- \u00e9s feln\u0151ttkorban kezd\u0151d\u0151 1-es t\u00edpus\u00fa diab\u00e9teszben.]\n                    Diabetol Hung. 2023; 31: 271\u2013278. [Hungarian]","DOI":"10.24121\/dh.2023.17"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Pande AK, Dutta D, Singla R. Prevention of type 1 diabetes: current\n                    perspective. Indian J Endocrinol Metab. 2023; 27: 277\u2013285.","DOI":"10.4103\/ijem.ijem_78_23"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Chen S, Du K, Zou C. Current progress in stem cell therapy for type\n                    1 diabetes mellitus. Stem Cell Res Ther. 2020; 11: 275.","DOI":"10.1186\/s13287-020-01793-6"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Wilson DM, Buckingham B. Prevention of type 1a diabetes mellitus.\n                    Pediatr Diabetes 2001; 2: 17\u201324.","DOI":"10.1046\/j.1399-543x.2001.00000.x-i3"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Winter WE, Schatz D. Prevention strategies for type 1 diabetes\n                    mellitus: current status and future directions. BioDrugs 2003; 17:\n                    39\u201364.","DOI":"10.2165\/00063030-200317010-00004"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Wilson SB, Kent SC, Patton KT, et al. Extreme Th1 bias of invariant\n                    V\u03b124J\u03b1Q T cells in type 1 diabetes. Nature 1998; 391(6663): 177\u2013181. Erratum:\n                    Nature 1999; 399(6731): 84.","DOI":"10.1038\/34419"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Brod SA, Atkinson M, Lavis VR, et al. Ingested IFN-\u03b1 preserves\n                    residual \u03b2 cell function in type 1 diabetes. J Interferon Cytokine Res. 2001;\n                    21: 1021\u20131030.","DOI":"10.1089\/107999001317205141"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Ludvigsson J, Heding L, Lied\u00e9n G, et al. Plasmapheresis in the\n                    initial treatment of insulin-dependent diabetes mellitus in children. Br Med J.\n                    1983; 286: 176\u2013178.","DOI":"10.1136\/bmj.286.6360.176"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Gale EA, Bingley PJ, Emmett CL, et al. European Nicotinamide\n                    Diabetes Intervention Trial (ENDIT): a randomised controlled trial of\n                    intervention before the onset of type 1 diabetes. Lancet 2004; 363:\n                    925\u2013931.","DOI":"10.1016\/S0140-6736(04)15786-3"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab,\n                    B-lymphocyte depletion, and preservation of beta-cell function. N Eng J Med.\n                    2009; 361: 2143\u20132152.","DOI":"10.1056\/NEJMoa0904452"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Singh N, Palmer JP. Therapeutic targets for the prevention of type 1\n                    diabetes mellitus. Curr Drug Targets Immune Endocr Metabol Disord. 2005; 5:\n                    227\u2013236.","DOI":"10.2174\/1568008054064823"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin\n                    in relatives of patients with type 1 diabetes: the diabetes prevention trial \u2013\n                    type 1. Diabetes Care 2005; 28: 1068\u20131076.","DOI":"10.2337\/diacare.28.5.1068"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Schatz DA, Bingley PJ. Update on major trials for the prevention of\n                    type I diabetes mellitus: the American Diabetes Prevention Trial (DPT-1) and the\n                    European Nicotinamide Diabetes Intervention Trial (ENDIT). J Pediatr Endocrinol\n                    Metab. 2001; 14(Suppl 1): 619\u2013622.","DOI":"10.1515\/JPEM.2001.14.S1.619"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Orb\u00e1n T, Farkas K, Jalahej H, et al. Autoantigen-specific regulatory\n                    T cells induced in patients with type 1 diabetes mellitus by insulin B-chain\n                    immunotherapy. J Autoimmun. 2010; 34: 408\u2013415.","DOI":"10.1016\/j.jaut.2009.10.005"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Ajmal N, Bogart MC, Khan P, et al. Emerging anti-diabetic drugs for\n                    beta-cell protection in type 1 diabetes. Cells 2023; 12: 1472.","DOI":"10.3390\/cells12111472"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Kordonouri O, Reschke F, Danne T. Teplizumab approval for type 1\n                    diabetes in the USA. Lancet Diabetes Endocrinol. 2023; 11:\n                    77\u201378.","DOI":"10.1016\/S2213-8587(22)00391-6"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Keam SJ. Teplizumab: first approval. Drugs 2023; 83:\n                    439\u2013445.","DOI":"10.1007\/s40265-023-01847-y"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody,\n                    teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019; 381:\n                    603\u2013613. Erratum: N Engl J Med. 2020; 382: 586.","DOI":"10.1056\/NEJMoa1902226"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Ramos EL, Dayan CM, Chatenoud L, et al. Teplizumab and \u03b2-cell\n                    function in newly diagnosed type 1 diabetes. N Engl J Med. 2023; 389:\n                    2151\u20132161.","DOI":"10.1056\/NEJMoa2308743"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Ludvigsson J, Faresj\u00f6 M, Hjorth M, et al. GAD treatment and insulin\n                    secretion in recent-onset type 1 diabetes. N Engl J Med. 2008; 359:\n                    1909\u20131920.","DOI":"10.1056\/NEJMoa0804328"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Ludvigsson J. Autoantigen treatment in type 1 diabetes: unsolved\n                    questions on how to select autoantigen and administration route. Int J Mol Sci.\n                    2020; 21: 1598.","DOI":"10.3390\/ijms21051598"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Dietrich F, Barcenilla H, Tavira B, et al. Immune response differs\n                    between intralymphatic or subcutaneous administration of GAD-alum in individuals\n                    with recent onset type 1 diabetes. Diabetes Metab Res Rev. 2022; 38:\n                    e3500.","DOI":"10.1002\/dmrr.3500"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Ludvigsson J, Sumnik Z, Pelikanova T, et al. Intralymphatic glutamic\n                    acid decarboxylase with vitamin D supplementation in recent-onset type 1\n                    diabetes: a double-blind, randomized, placebo-controlled phase IIb trial.\n                    Diabetes Care 2021; 44: 1604\u20131612.","DOI":"10.2337\/dc21-0318"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Puente-Marin S, Dietrich F, Achenbach P, et al. Intralymphatic\n                    glutamic acid decarboxylase administration in type 1 diabetes patients induced a\n                    distinctive early immune response in patients with DR3DQ2 haplotype. Front\n                    Immunol. 2023; 14: 1112570.","DOI":"10.3389\/fimmu.2023.1112570"},{"key":"R37","unstructured":"Banting FG, Best CH, Collip JB, et al. Pancreatic extracts in the\n                    treatment of diabetes mellitus. Can Med Assoc J. 1922; 12:\n                    141\u2013146."},{"key":"R38","doi-asserted-by":"crossref","unstructured":"Kent SC, Chen Y, Clemmings SM, et al. Loss of IL-4 secretion from\n                    human type 1a diabetic pancreatic draining lymph node NKT cells. J Immunol.\n                    2005; 175: 4458\u20134464.","DOI":"10.4049\/jimmunol.175.7.4458"},{"key":"R39","doi-asserted-by":"crossref","unstructured":"Kis JT, Engelmann P, Orb\u00e1n T. Insulin A-chain autoreactive T cells\n                    in newly diagnosed type 1 diabetic patients\u2019 blood. [Inzulin A-l\u00e1nca elleni\n                    autoreakt\u00edv T-sejtek izol\u00e1lhat\u00f3ak \u00fajonnan diagnosztiz\u00e1lt 1-es t\u00edpus\u00fa\n                    cukorbetegek v\u00e9r\u00e9b\u0151l.] Diabetol Hung. 2021; 29: 99\u2013103.\n                    [Hungarian]","DOI":"10.24121\/dh.2021.9"},{"key":"R40","doi-asserted-by":"crossref","unstructured":"Thompson PJ, Pipella J, Rutter GA, et al. Islet autoimmunity in\n                    human type 1 diabetes: initiation and progression from the perspective of the\n                    beta cell. Diabetologia 2023; 66: 1971\u20131982.","DOI":"10.1007\/s00125-023-05970-z"},{"key":"R41","doi-asserted-by":"crossref","unstructured":"Winkler G, Kis JT, Schandl L. Is there a need for a revised\n                    classification in diabetes mellitus? [Indokolt-e a klasszifik\u00e1ci\u00f3 m\u00f3dos\u00edt\u00e1sa\n                    diabetesben?] Orv Hetil. 2022; 163: 1909\u20131916. [Hungarian]","DOI":"10.1556\/650.2022.32639"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/165\/10\/article-p363.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/165\/10\/article-p363.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/165\/10\/article-p363.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:42:21Z","timestamp":1784810541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/165\/10\/article-p363.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,10]]},"references-count":41,"journal-issue":{"issue":"10"},"URL":"https:\/\/doi.org\/10.1556\/650.2024.33000","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,10]]}}}